Post Reply
6441-6460 of 10899
He always like to hide behind his televisison set, then come out and cow pei cow bu and start slandering me when BIG share price goes down. Hopeless fellow. Cannot see there is bloodbath everywhere.
jackjames ( Date: 03-Jul-2008 12:15) Posted:
|
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Wednesday July 2, 4:50 pm ET
- XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over
Market-Leading Stent in Clinical Trials, Now Available in United States for
Treatment of Coronary Artery Disease
ABBOTT PARK, Illinois, July 2 /PRNewswire/ -- Abbott today announced that the U.S. Food and Drug Administration (FDA) approved the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE V is the only drug eluting stent to have demonstrated superiority over Boston Scientific's TAXUS® paclitaxel-eluting coronary stent system in two randomized head-to-head clinical trials. XIENCE V will be launched in the United States immediately.
"XIENCE V represents an important treatment advance for the estimated 13 million people in the United States suffering from coronary artery disease, and we believe XIENCE V will quickly become the new standard for drug eluting stents given its outstanding clinical results," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Physicians in the United States have been waiting for years to treat their patients with a technology that delivers on the promise of drug eluting stents through both ease of use and excellent clinical performance, and XIENCE V is that technology."
The XIENCE V drug coated stent is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. Coronary artery disease occurs when plaque build-up narrows the arteries and reduces blood flow to the heart, which can lead to chest pain or a heart attack.
"XIENCE V was designed to improve safety and efficacy compared to earlier generation stents. The long-term clinical data from two studies performed in both the United States and Europe have now confirmed that XIENCE V is a true next-generation drug eluting stent with clinically important benefits for patients," said Gregg W. Stone, M.D., Columbia University Medical Center; chairman, Cardiovascular Research Foundation, New York; and principal investigator of the SPIRIT III U.S. pivotal clinical trial for XIENCE V.
Clinical Data Supporting XIENCE V
The robust clinical program for XIENCE V includes long-term data from a total of 1,362 patients enrolled in the SPIRIT FIRST, SPIRIT II and SPIRIT III trials, as well as continued access and post-approval programs that will enroll more than 14,000 XIENCE V patients.
The FDA approved XIENCE V based, in large part, on superior results from the 1,002 patient SPIRIT III U.S. pivotal clinical trial, in which XIENCE V demonstrated statistical superiority to TAXUS on the study's primary endpoint of in-segment late loss (vessel renarrowing) at eight months, with a statistically significant 50 percent reduction (mean, 0.14 mm for XIENCE V vs. 0.28 mm for TAXUS). XIENCE V also demonstrated statistical non-inferiority to TAXUS in the co-primary endpoint of target vessel failure (TVF, cardiac events related to the stented vessel) at nine months, with an observed 20 percent reduction (7.2 percent for XIENCE V vs. 9.0 percent for TAXUS). TVF is a composite clinical measure of safety and efficacy outcomes defined as cardiac death, heart attack (myocardial infarction or MI) or target vessel revascularization (TVR).
In May 2008, Abbott presented two-year data from the SPIRIT III trial demonstrating that XIENCE V continues to deliver positive clinical benefits for patients. At two years, the XIENCE V demonstrated the following key results:
-- A 45 percent reduction in the risk of major adverse cardiac events (MACE) compared to TAXUS (7.3 percent for XIENCE V vs. 12.8 percent for TAXUS, p-value=0.004)*. MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (MI) or ischemia-driven target lesion revascularization (TLR, repeat procedures driven by lack of blood supply).
-- A 32 percent reduction in the risk of TVF compared to TAXUS (10.7 percent for XIENCE V vs. 15.4 percent for TAXUS, p-value=0.04)*.
-- Low rates of stent thrombosis between one and two years, defined as very late stent thrombosis, per Academic Research Consortium (ARC) definition of definite/probable stent thrombosis (0.3 percent for XIENCE V and 1.0 percent for TAXUS) and per the SPIRIT III protocol (0.2 percent for XIENCE V and 1.0 percent for TAXUS). The ARC definition of late stent thrombosis was developed to eliminate variability in the definitions across various drug eluting stent trials.
"Today's approval of XIENCE V is a reflection of Abbott's ongoing commitment to bring innovation-driven, leading-edge medical technologies to the people who need them," added Capek. "With one of the largest, most seasoned vascular sales forces in the United States and with the ability to supply more than half the worldwide market, we will begin shipping units of XIENCE V immediately to meet physician demand for this much awaited, next-generation technology."
Children do not INVEST in stock and shares. Adults should know what caveat emptor means. If you buy something on impulse with both eyes shut please do not direct blame at others.
Maybe all overall bullish...at that time possibel but today want to clear $0.80cts also gone liao,over bullish time pple want to buy lexus using gains from BIG,downgrade to proton saga and today maybe lose till pants drop-red underwear or never wear or no wear,it's dead now until when mkt recovers may be 2 to 3 years time
novena_33 ( Date: 01-Jul-2008 14:53) Posted:
|
Don't blame the brokers or mkt sentiments,day 1 when our dispute over BIG,my proposition is drug/medical co very volatile and not much fudamentals esp vast amt of $$$ spent on research,long time to bear fruits or 'peanuts" U come up with all impressive cut and paste and contingent on Biomatrix and no with or without the latter it's downhill for historical low-BIG can't defy gravity too so yr $1.20 TP by Aug still hold.sori no offence meant against U but wonder how many had died since the Day when BIG came down from $1.50 to $1.30 to $1.20 ...$1.16 ,$1.10 and <$1.00 and finally $).605,looks like heading even lower
bengster68 ( Date: 02-Jul-2008 17:57) Posted:
|
finally LCD is back.
Mr bengster,I belive many pple still buy base on yr recommendation from 68 to 83cts level and now at 60.5cts U still talk ab support level,looks . like heading for 55cts,where are yr loyal supporters now?
bengster68 ( Date: 02-Jul-2008 17:57) Posted:
|
50 cents is on the way!!
Sorry i meant support level, not resistance level.
Can consider buy at resistance level. If resistance broken, technically bearish and can consider cut loss. But sometimes shorties like to break the share price just below resistance level so chart investors will all swamp to sell off their holdings. This is when the shortie will cover back. Shortie very Chiak Ark ah........ you kena margin call, they will be very happy you cannot pay. Buy within your means and don't over stretch. Nothing is certain in stock market. This is a crocodile pool.
no eye see leow, may break 60 if CO don't calm down these few days.
Market sentiment is very bad. Local house traders shorting second liner stocks today. Shorting with no volume means they waiting to cover back soon. Those retail clients that cannot make margin call cash top up will be force sold. When brokerage house force sell, they will time it and do it at the same time. This is when their own in-house traders will cover back cheap. Maybe kena second round again as long as market sentiment remain bad. Dirty brokerage business tricks. If later this month show Q2 results are ok, the bear will retreat (provided oil don't shoot higher). Fundamentals of BIG does not change overnight just because 0.5% of their issued shares traded lower this week.
it just can't resist the market's force, despite the amazing comments in the annual report. jiat lut.
hv enough leow, no intention to do avg though the price now is rather attracting.
Mr. Beng, are u doing cost averaging now?
0.615 now.... walau... thought they are rock solid ....
Hv rcv the notice of AGM. Its on 22 this mth. Ha ha, must look around first lah before putting up my both hands to against/for the Resolutions.
beside issuing extra shares, paying directors' fee of $252,667.00 is one of the resolutions as well. this may invide some noises as coy is not doing well loh.
wonder if the sell down is related to news of BIG issuing more shares to takeover JWMS...
What support are we talking about now??
good post. simple yet effective and on the dot, u are on the way as a pro trader!